Dr. Tsai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 Parnassus Ave
San Francisco, CA 94143Phone+1 415-476-1000
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2013 - 2015
University of North Carolina HospitalsResidency, Internal Medicine, 2010 - 2013
The Warren Alpert Medical School of Brown UniversityClass of 2010
Certifications & Licensure
CA State Medical License 2013 - 2026
NC State Medical License 2010 - 2013
Clinical Trials
- Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors Start of enrollment: 2020 Jun 16
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 8 citationsRe-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.Adriana Hepner, Victoria Atkinson, James Larkin, Rebecca A. Burrell, Matteo S. Carlino
European Journal of Cancer. 2021-06-28 - 269 citationsClinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.Alain Algazi, Katy K. Tsai, Alexander N. Shoushtari, Rodrigo Ramella Munhoz, Zeynep Eroglu
Cancer. 2016-11-01 - 211 citationsThe efficacy of anti-PD-1 agents in acral and mucosal melanoma.Alexander N. Shoushtari, Rodrigo Ramella Munhoz, Deborah Kuk, Patrick A. Ott, Douglas B. Johnson
Cancer. 2016-11-01
Press Mentions
UCSF Health Cancer Experts Featured at Premier Cancer MeetingJune 4th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
